Ambrx Biopharma — Corporate Update (October 2022)
21 slides from Ambrx Biopharma's corporate update, Oct 18, 2022
Slide 1: Strategic Reprioritization and Corporate Update
Strategic Reprioritization and Corporate Update NYSE: AMAM October 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 © 2022 Ambrx Biopharma Inc. All rights reserved Certain statements contained in this presentation, other than statements of historical fact, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking stat
Slide 3: Strategic Review Outcome: Overview
Strategic Review Outcome: Overview © 2022 Ambrx Inc. All rights reserved Key Objectives Extend runway from end of year 2023 into 2025 Clear development focus Advance first-in-class and best-in-class pipeline Reprioritization of Development Pipeline Company focus on oncology Streamlining positions Am
Slide 4: Reprioritization of Development Pipeline
Reprioritization of Development Pipeline 4 © 2022 Ambrx Inc. All rights reserved ARX517 (Anti-PSMA for Prostate Cancer) – Ambrx sponsored Significant unmet medical need in prostate cancer Proprietary, site-specific conjugation platform that provides homogenous antibody-drug conjugates (ADCs) with un
Slide 5: Strong Cash Position
Strong Cash Position © 2022 Ambrx Inc. All rights reserved Cash position of $129.7 million as of June 30, 2022 Reprioritization of pipeline and streamlining of organization enables funding of operations into 2025 Prioritized programs expected to be funded through key milestones: ARX517: Funded throu
Slide 6: ARX788 Out-Licensing Opportunity
ARX788 Out-Licensing Opportunity
Slide 7: ARX788: Out-Licensing of HER2 Positive Assets
ARX788: Out-Licensing of HER2 Positive Assets © 2022 Ambrx Inc. All rights reserved Highly Competitive Landscape Metastatic breast cancer landscape overall has become highly competitive HER2+ alone is very competitive, with approximately 175 trials While majority could produce post-T-DXd data, curre
Slide 8: Strengthening Development Pipeline
Strengthening Development Pipeline
Slide 9: Focused Development Pipeline on EPBs in Oncology
Focused Development Pipeline on EPBs in Oncology 9 © 2022 Ambrx Inc. All rights reserved Transition to Earlier Stage Development Company Ambrx will focus on earlier stage development assets with the greatest potential and strong competitive profiles Leverage Ambrx’s unique enabling technology platfo
Slide 10: Internal Pipeline Reprioritization
© 2022 Ambrx Biopharma Inc. All rights reserved Candidate Indications Trial Setting (Name) Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone(s) Ambrx Rights Engineered Precision Biologics for Oncology ARX517 Anti-PSMA ADC PSMA + solid tumors APEX-01 Interim Phase 1a safety data in 2H202
Slide 11: ARX517 (Anti-PSMA ADC): Promising ADC for mCRPC and PSMA Expressing Solid Tumors
ARX517 (Anti-PSMA ADC): Promising ADC for mCRPC and PSMA Expressing Solid Tumors Potential for treating PSMA over-expressed cancer such as prostate cancer, especially in metastatic castration-resistant prostate cancer (mCRPC) Potent in vivo anti-tumor demonstrated in both enzalutamide sensitive and
Slide 12: ARX517: Prioritized Lead Asset
ARX517: Prioritized Lead Asset 12 © 2022 Ambrx Inc. All rights reserved ARX517 Targets High Unmet Medical Need Prostate cancer represents a significant unmet medical need 1.4 million annual new cases worldwide; an estimated $9.9 billion treatment market (2020) PSMA remains a meaningful and de-risked
Slide 13: ARX305 (Anti-CD70 ADC): Potent Anti-Tumor Activities in RCC Xenograft Models
ARX305 (Anti-CD70 ADC): Demonstrated Potent Anti-Tumor Activities in Multiple RCC Xenograft Models ARX305 is designed to address issues observed with earlier generations of CD70 ADCs through: Enhanced mAb-payload stability to confer wider therapeutic window and reduce toxicity CD70 is overexpressed
Slide 14: ARX305 Leverage Partnership Results for Internal Development
ARX305 © 2022 Ambrx Inc. All rights reserved Leverage Partnership Results for Internal Development Ambrx’s China partner, NovoCodex, initiated Phase 1 trial for ARX305 in 2H 2022 Ambrx intends to leverage NovoCodex’s data to inform internal ARX305 trial Prevents duplicate efforts in safety and effic
Slide 15: ARX102 (Smart IL-2): Designed to Stimulate Immune System
ARX102 (Smart IL-2): Designed to Stimulate Immune System by Targeting β and γ (While Sparing α) Receptors on T-Cell ARX102 Increased CD8+ in Tumor Site (CT26 Model) Vehicle ARX102 (3mg/kg) Dose-response Activity of ARX102 in E0771 Syngeneic Breast Cancer Model Precision-engineered Smart IL-2 molecul
Slide 16: ARX102 Leverage Partnership Results for Internal Development
ARX102 16 © 2022 Ambrx Inc. All rights reserved Leverage Partnership Results for Internal Development Sino Biopharm expects to file IND for ARX102 in China in 2022 Subsequent initiation of Phase 1 trial in China in 1H 2023 Ambrx will leverage Sino Biopharm’s data to inform internal ARX102 Phase 1a t
Slide 17: Summary
AMBRX Summary Ef. oa "a Le AMBRX
Slide 18: Strategic Review Outcome: Overview
Strategic Review Outcome: Overview © 2022 Ambrx Inc. All rights reserved Key Objectives Extend runway from end of year 2023 into 2025 Clear development focus Advance first-in-class and best-in-class pipeline Reprioritization of Development Pipeline Company focus on oncology Streamline development sc
Slide 19: Thank You
Thank You
Slide 20: Appendix: Ongoing Partnered Programs
Appendix: Ongoing Partnered Programs
Slide 21: Ongoing Partnered Programs Pipeline
21 © 2022 Ambrx Biopharma Inc. All rights reserved Candidate Indications Trial Setting (Name) Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone(s) Ambrx Rights ADC Oncology ARX788 Anti-HER2 ADC HER2+ mBC (FDA granted Fast Track Designation and NMPA granted Breakthrough Designation for H